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Background:  Compared to the bare metal Express stent (BMS), the TAXUS Element (ION) Paclitaxel-eluting platinum chromium stent (DES) has 
been shown to significantly reduce major adverse cardiovascular events (MACE) in patients with small vessel coronary artery disease. An economic 
analysis quantified the incremental cost-effectiveness of the new stent platform.
Methods:  A Markov model was developed comparing total costs from a Medicare perspective over 1 year of the ION DES vs BMS, based on 
clinical outcomes in the PERSEUS SV trial (treated vessel diameters ≥2.25 mm - <2.75 mm). Economic outcomes are reported in terms of cost per 
clinical event avoided.
Results:  The ION DES was found to be cost saving relative to the BMS from a payer perspective, driven by the reduced rate of target vessel 
revascularization (TVR). Higher index procedure cost for DES partially offset the lower TVR cost. Use of the ION DES is cost saving by an average of 
$710/patient (table). Probabilistic sensitivity analyses, varying clinical parameters across their confidence intervals to create statistically plausible 
sets, show ION DES is economically dominant (more effective and less costly) in 83% of these parameter sets with an incremental cost <$10,000 
per MACE avoided in a further 14%.
Conclusions:  Cost-effective analysis shows an economic advantage of the TAXUS Element (ION) stent vs BMS in small vessels. This analysis sets 
the stage for further assessment of new stent platforms to evaluate the economic benefit of medical innovation.
